Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor-beta1

J Biol Chem. 2001 Jan 12;276(2):1653-9. doi: 10.1074/jbc.M008170200.

Abstract

The inducible isoform of nitric-oxide synthase (NOS2) catalyzes the production of nitric oxide (NO), which participates in the pathophysiology of systemic inflammatory diseases such as sepsis. NOS2 is transcriptionally up-regulated by endotoxin and inflammatory cytokines, and down-regulated by transforming growth factor (TGF)-beta1. Recently we have shown that high mobility group (HMG)-I(Y) protein, an architectural transcription factor, contributes to NOS2 gene transactivation by inflammatory mediators. The aim of the present study was to determine whether regulation of HMG-I(Y) by TGF-beta1 contributes to the TGF-beta1-mediated suppression of NOS2. By Northern blot analysis, we show that TGF-beta1 decreased cytokine-induced HMG-I(Y) mRNA levels in vascular smooth muscle cells and macrophages in vitro and in vivo. Western analysis confirmed the down-regulation of HMG-I(Y) protein by TGF-beta1. To determine whether the down-regulation of HMG-I(Y) contributed to a decrease in NOS2 gene transactivation by TGF-beta1, we performed cotransfection experiments. Overexpression of HMG-I(Y) was able to restore cytokine inducibility of the NOS2 promoter that was suppressed by TGF-beta1. The effect of TGF-beta1 on NOS2 gene transactivation was not related to a decrease in binding of HMG-I(Y) to the promoter of the NOS2 gene, but due to a decrease in endogenous HMG-I(Y) protein. These data provide the first evidence that cytokine-induced HMG-I(Y) can be down-regulated by TGF-beta1. This down-regulation of HMG-I(Y) contributes to the TGF-beta1-mediated decrease in NOS2 gene transactivation by proinflammatory stimuli.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Aorta
  • Cell Line
  • Cells, Cultured
  • Gene Expression Regulation* / drug effects
  • Gene Expression Regulation, Enzymologic / drug effects
  • HMGA1a Protein
  • High Mobility Group Proteins / genetics*
  • High Mobility Group Proteins / metabolism
  • Interferon-gamma / pharmacology
  • Macrophages / enzymology
  • Male
  • Mice
  • Muscle, Smooth, Vascular / metabolism*
  • Nitric Oxide Synthase / genetics*
  • Nitric Oxide Synthase Type II
  • Phosphoproteins / genetics
  • Promoter Regions, Genetic
  • RNA, Messenger / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / metabolism
  • Transcription Factors / genetics*
  • Transcription Factors / metabolism
  • Transcription, Genetic / drug effects*
  • Transcriptional Activation
  • Transfection
  • Transforming Growth Factor beta / pharmacology*

Substances

  • High Mobility Group Proteins
  • Phosphoproteins
  • RNA, Messenger
  • Recombinant Proteins
  • Transcription Factors
  • Transforming Growth Factor beta
  • HMGA1a Protein
  • Interferon-gamma
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Nos2 protein, rat